Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.
Adachi JD, Lyles KW, Colón-Emeric CS, Boonen S, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Bucci-Rechtweg C, Su G, Eriksen EF, Magaziner JS. Adachi JD, et al. Osteoporos Int. 2011 Sep;22(9):2539-49. doi: 10.1007/s00198-010-1514-9. Epub 2011 Jan 20. Osteoporos Int. 2011. PMID: 21249332 Clinical Trial.
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS. Orwoll ES, et al. J Bone Miner Res. 2010 Oct;25(10):2239-50. doi: 10.1002/jbmr.119. J Bone Miner Res. 2010. PMID: 20499357 Free article. Clinical Trial.
Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW; HORIZON Recurrent Fracture Trial. Boonen S, et al. J Am Geriatr Soc. 2011 Nov;59(11):2084-90. doi: 10.1111/j.1532-5415.2011.03666.x. Epub 2011 Oct 21. J Am Geriatr Soc. 2011. PMID: 22091563 Clinical Trial.
Clinical risk factors for recurrent fracture after hip fracture: a prospective study.
Colón-Emeric CS, Lyles KW, Su G, Pieper CF, Magaziner JS, Adachi JD, Bucci-Rechtweg CM, Haentjens P, Boonen S; HORIZON Recurrent Fracture Trial. Colón-Emeric CS, et al. Calcif Tissue Int. 2011 May;88(5):425-31. doi: 10.1007/s00223-011-9474-4. Epub 2011 Feb 18. Calcif Tissue Int. 2011. PMID: 21331567 Clinical Trial.
Association between timing of zoledronic acid infusion and hip fracture healing.
Colón-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C; HORIZON Recurrent Fracture Trial. Colón-Emeric C, et al. Osteoporos Int. 2011 Aug;22(8):2329-36. doi: 10.1007/s00198-010-1473-1. Epub 2010 Dec 9. Osteoporos Int. 2011. PMID: 21153021 Clinical Trial.
Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams.
Reid IR, Black DM, Eastell R, Bucci-Rechtweg C, Su G, Hue TF, Mesenbrink P, Lyles KW, Boonen S; HORIZON Pivotal Fracture Trial and HORIZON Recurrent Fracture Trial Steering Committees. Reid IR, et al. J Clin Endocrinol Metab. 2013 Feb;98(2):557-63. doi: 10.1210/jc.2012-2868. Epub 2013 Jan 4. J Clin Endocrinol Metab. 2013. PMID: 23293335 Clinical Trial.
36 results